Precision Neuroscience, a neurotech startup, achieved a major milestone on Thursday with the U.S. Food and Drug Administration’s approval of a core component of its brain implant system. The company is developing a brain-computer interface (BCI), designed to decode neural signals and translate them into commands for external devices. Initially, the BCI aims to help patients with severe paralysis regain functions like speech and movement.
The FDA approved part of Precision’s system, marking the first full regulatory clearance granted to a company working on a wireless BCI. Other notable players in the field include Neuralink, founded by Elon Musk, and Synchron, backed by high-profile investors such as Jeff Bezos and Bill Gates.
Dr. Benjamin Rapoport, Precision’s co-founder and chief science officer, described the approval as a “foundational moment” for the company. Rapoport, who also co-founded Neuralink before leaving the company in 2018, noted the significance of the approval for the BCI industry. The approved component, known as the Layer 7 Cortical Interface, is a microelectrode array thinner than a human hair. The array consists of 1,024 electrodes capable of recording, monitoring, and stimulating electrical activity on the brain’s surface. When implanted, it conforms to the brain’s surface without causing tissue damage.
The FDA cleared Layer 7 for temporary implantation of up to 30 days in patients. This approval allows Precision to market the technology for clinical use, enabling surgeons to use it during procedures to map brain signals. While this is not the final goal for the technology, it will allow Precision to generate revenue in the short term.
To date, Precision has temporarily implanted Layer 7 in 37 patients, primarily during brain surgeries for medical reasons. With FDA clearance, the company can now collect data over extended periods, enhancing the effectiveness of its BCI systems.
“This regulatory clearance will exponentially increase our access to diverse, high-quality data, helping us build better BCI systems,” said Rapoport, highlighting the potential of this technology in transforming patient care.
READ MORE: